Pune, India, January 2019/MRFR Press Release/- Market Research Future has published a half-cooked research report on the Global Mitochondrial Myopathy Diagnosis & Treatment Market.
In Mitochondrial myopathy, the mitochondria are affected which leads to symptoms such as muscle weakness, muscle cramping, low immunity, poor balance, and fatigue. Mitochondrial myopathy interferes with the functioning of the muscles and might also affect the functioning of other organs. At present, there is no curative therapy for mitochondrial myopathy. As per the analysis of Market Research Future (MRFR), the global mitochondrial myopathy market is expected to exhibit an upswing and attain USD 33.6 Mn at a CAGR of 9.82% by the end of the forecast period of 2017-2020.
The growth in the global mitochondrial myopathy diagnosis & treatment market can be attributed to various factors. The spiraling rise in the incidence rate of mitochondrial myopathy is a key factor in boosting the growth of the market. As per the Australian Mitochondrial Disease Foundation (AMFD), about one in 5,000 people are likely to develop a significant mitochondrial disease. A growing number of mitochondrial myopathy cases generate massive demand for diagnosis and treatment which is well complemented by the rise in a number of screening services. Higher awareness regarding the disease has led to the development of various screening methods. Government support in the form of funding and incentives for rare genetic diseases has promoted the growth of the market. In addition, rigorous R&D activities aimed at developing therapies and treatments for mitochondrial myopathy have encouraged the growth of the market. Furthermore, a growing number of clinical trials to develop effective drugs for the disease along with the rise in a number of FDA approvals for novel drugs and therapies have proven to be beneficial for the growth of the market. On the downside, the growth of the market might be met by various bottlenecks. Lack of proper curative treatment and poor treatment options remain a major hurdle for the market growth. Due to low awareness, the diagnosis of the disease remains considerably low, especially in the developing and underdeveloped countries. Besides, the rare nature of the disease and high cost of drug development along with high investment risk remain major challenges to the growth of the market. Nevertheless, faster market uptake and low marketing cost are likely to present growth opportunities to the global mitochondrial myopathy diagnosis & treatment market.
The global mitochondrial myopathy diagnosis & treatment market has been segmented based on type, diagnostic tests, and therapy.
By type, the global mitochondrial myopathy diagnosis & treatment market has been segmented into neuropathy, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), progressive external ophthalmoplegia (PEO), Pearson syndrome, Leigh syndrome, ataxia, mitochondrial DNA depletion syndrome (MDS), Retinitis pigmentosa (NARP), Kearns–Sayre syndrome (KSS), myoclonic epilepsy with ragged red fibres (MERRF), mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE). The MELAS is the largest segment and is foreseen to capture a CAGR of 19.39% during 2017-2020.
By diagnostic test, the global mitochondrial myopathy diagnosis & treatment market has been segmented into genetic tests, muscle biopsy, and biochemical test. The genetic tests segment was the largest segment in 2016 and is projected to grow at a CAGR of 10.11% over the forecast period.
By therapy, the global mitochondrial myopathy diagnosis & treatment market has been segmented into supportive therapy and targeted therapy. The supportive therapy segment held the largest market share in 2016 and is projected to capture a CAGR of 9.82% over the forecast period.
By region, the global mitochondrial myopathy diagnosis & treatment market has been segmented into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The Americas dominate the global market on account of favorable reimbursement landscape and high healthcare expenditure. The region has a general propensity to adopt new technologies earlier as compared to other regions which are an advantage for the growth of the Americas market. The Americas mitochondrial myopathy diagnosis & treatment market is anticipated to reach USD 116.7 Mn at a CAGR of 19.39% by the end of the forecast period of 2017-2020.
Europe is the second largest market for mitochondrial myopathy diagnosis & treatment spurred by high disposable income and surging awareness in the region.
The APAC mitochondrial myopathy diagnosis & treatment market is expected to reach USD 4.4 Mn at a CAGR of 9.94% by the end of the forecast period.
The MEA market is led by the Gulf nations of Saudi Arabia and UAE. The Africa region is expected to showcase moderate growth due to poor economic condition prevailing in the region and low healthcare penetration.
The notable players in the global mitochondrial myopathy diagnosis & treatment market include Stealth Biotherapeutics, Khondrion BV, NeuroVive Pharmaceutical AB, Reata Pharmaceuticals Inc., GeneDx, Mitobridge, Centogene AG, and Ixchel Pharma.
In January 2019, Stealth Bio Therapeutics announced selling USD 86.25 of its common stock in an IPO for advancing drug candidates for the treatment of mitochondrial-based conditions. The finding will support the development of drugs to treat mitochondrial dysfunction.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/mitochondrial-myopathy-diagnosis-treatment-market-3950